Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review

Sleep Medicine

Volumn 14, Issue 1, 2013, Pages 30-36

  Nittur, Nandini ^a,b,c   Konofal, Eric ^a,b,d   Dauvilliers, Yves ^a,e,f   Franco, Patricia ^a,g   Leu Semenescu, Smaranda ^a,b,c   Cock, Valérie Cochen De ^a,e,f   Inocente, Clara O ^a,g   Bayard, Sophie ^a,e,f   Scholtz, Sabine ^a,e,f   Lecendreux, Michel ^a,d   Arnulf, Isabelle ^a,b,c,e  

^a Idiopathic Hypersomnia   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e INSERM   (France)

^f GUI DE CHAULIAC HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

Author keywords

Cataplexy; Idiopathic hypersomnia; Mazindol; Narcolepsy; Observational study; Sleepiness

Indexed keywords

ATENOLOL; CLOMIPRAMINE; IVABRADINE; MAZINDOL; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PHENTERMINE RESIN; VENLAFAXINE; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANORGASMIA; APNEA; ARTICLE; CATAPLEXY; CHILD; CHOLESTASIS; CONSTIPATION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EPWORTH SLEEPINESS SCALE; FEMALE; HEART PALPITATION; HUMAN; HYPERSOMNIA; HYPERTENSION; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NARCOLEPSY; NAUSEA; NERVOUSNESS; NIGHTMARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREMOR; VITAL SIGN; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; HEART RATE; HUMANS; HYPERSOMNOLENCE, IDIOPATHIC; MALE; MAZINDOL; MIDDLE AGED; NARCOLEPSY; RETROSPECTIVE STUDIES; WAKEFULNESS; YOUNG ADULT;

EID: 84872339899     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.07.008     Document Type: Article

References (23)

1. Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers GJ., Mayer G., et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006, 13:1035-1048.
2. Morgenthaler T., Kapur V., Brown T., Swick T., Alessi C., Aurora R., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1705-1711.
3. Lin J.S., Dauvilliers Y., Arnulf I., Bastuji H., Anaclet C., Parmentier R., et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008, 30:74-83.
4. Lavault S., Dauvilliers Y., Drouot X., Leu-Semenescu S., Golmard JL., Lecendreux M., et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 2011, 12:550-556.
5. Gogerty J., Trapold J. Chemistry and pharmacology of mazindol. Triangle 1976, 15:25-36.
6. Defelice E.A., Chaykin L.B., Cohen A. Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity. Curr Ther Res Clin Exp 1973, 15:358-366.
7. Aeberli P., Eden P., Gogerty J.H., et al. 5-Aryl-2,3-dihydro-5H-imidazo [2,1-a]isoindol-5-ols. A novel class of anorectic agents. J Med Chem 1975, 18:177-182.
8. Sharma R., Collipp P., Rezvani I., Strimas J., Maddaiah V., Rezvani E. Clinical evaluation of the anorexic activity and safety of 42-548 in children. Clin Pediatr 1973, 12:145-149.
9. Evans E., Wallace M. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland. Curr Med Res Opin 1975, 3:132-137.
10. Parkes J.D., Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand 1979, 60:250-254.
11. Shindler J., Schachter M., Brincat S., Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed) 1985, 290:1167-1170.
12. Iijima S., Sugita Y., Teshima Y., Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986, 9:265-268.
13. Vespignani H., Weber M., Atlas P., Barroche G. Value of mazindol in Gelineau's disease. A propos of 10 cases. Rev Electroencephalogr Neurophysiol Clin 1986, 16:317-322.
14. Boutet K., Frachon I., Jobic Y., Gut-Gobert C., Leroyer C., Carlhant-Kowalski D., et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009, 33:684-688.
15. Frachon I., Etienne Y., Jobic Y., Le Gal G., Humbert M., Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One 2010, 5:e10128.
16. American Academy of Sleep Medicine. The international classification of sleep disorders - revised. In: Hauri P, editor. Chicago, IL: American Academy of Sleep Medicine; 2005.
17. Parkes D., Schachter M. Clomipramine and clonazepam in narcolepsy. Lancet 1979, 2:1085-1086.
18. Enzi G., Baritussio A., Marchiori E., Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976, 4:305-319.
19. Inoue S. Clinical studies with mazindol. Obes Res 1995, 3(Suppl.):549S-552S.
20. Segraves R.T. Antidepressant-induced orgasm disorder. J Sex Marital Ther 1995, 21:192-201.
21. Bradley M., Blum N., Scheib R. Mazindol in obesity with known cardiac disease: a clinical evaluation. J Int Med Res 1974, 2:347-349.
22. Hagiwara M., Tsuchida A., Hyakkoku M., Nishizato K., Asai T., Nozawa Y., et al. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol. Jpn Circ J 2000, 64:218-221.
23. Vetter V.L., Elia J., Erickson C., Berger S., Blum N., Uzark K., et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008, 117:2407-2423.